LAUSR

ABSTRACT Introduction Wearable cardioverter-defibrillator (WCD) is a novel tool that may be of interest in situations with atransient risk of sudden cardiac death. It offers a temporary and easy to remove protection against malignant ventricular arrhythmias. In this review, the authors describe evidence in literature and different international guidelines and consensus. Areas covered The authors searched PubMed, Cochrane Central Register of controlled trials, and Google Scholar for relevant studies and comments. Expert Opinion If a WCD is indicated, the observance must be as perfect as possible. Thus, patients need proper education in wearing the WCD. The temporary use of a WCD is reasonable in patients with a high risk for SCD, even with a low level of evidence with only one randomized clinical trial (VEST), as its disadvantages are limited to a transitory impairment in quality of life and a low risk of inappropriate shock. Indications are now well accepted: ischemic cardiomyopathy with LVEF below 35% before reassessment, recent onset of NICM or presumed myocarditis with LVEF ≤35% before reassessment, after ICD explant until reimplantation (e.g. infection), and bridge to transplant. Future guidelines on WCD in the prevention of SCD may be warranted to harmonize clinical practice especially in debated indications..